MedTrace Logo

Immunological Profiling of Patients With COVID-19 in Respiratory Distress

NCT04351711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-12-10

No results posted yet for this study

Summary

The study investigators hypothesize that the pneumonia arising in patients with COVID-19 is largely of immunopathological origin. The investigators will therefore seek to define the immune activation phenotype of patients in respiratory distress and to see if this immune signature is predictive of mortality. Finally, the investigators will look for overproduced inflammatory mediators to identify potential therapeutic targets.

Conditions

Interventions

OTHER

Immunological profiling

The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers

OTHER

Immunological profiling

The immune activation phenotype will be assessed using a standardized panel of soluble and membrane immune activation markers

Sponsors & Collaborators

  • Institute of Human Genetics, Montpellier

    collaborator UNKNOWN

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Principal Investigators

  • Pierre Corbeau · CHU Nimes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2022-12-12
Completion
2022-12-12

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351711 on ClinicalTrials.gov